Outset Medical, Inc. (OM)
| Market Cap | 68.47M -64.4% |
| Revenue (ttm) | 117.59M +2.0% |
| Net Income | -74.85M |
| EPS | -4.15 |
| Shares Out | 18.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 384,333 |
| Open | 4.050 |
| Previous Close | 4.680 |
| Day's Range | 3.570 - 4.135 |
| 52-Week Range | 3.000 - 21.980 |
| Beta | 1.91 |
| Analysts | Strong Buy |
| Price Target | 13.33 (+260.76%) |
| Earnings Date | May 7, 2026 |
About OM
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and Tablo... [Read more]
Financial Performance
In 2025, Outset Medical's revenue was $119.48 million, an increase of 5.09% compared to the previous year's $113.69 million. Losses were -$81.65 million, -36.20% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for OM stock is "Strong Buy." The 12-month stock price target is $13.33, which is an increase of 260.76% from the latest price.
News
Outset Medical price target lowered to $10 from $12 at TD Cowen
TD Cowen analyst Joshua Jennings lowered the firm’s price target on Outset Medical (OM) to $10 from $12 and keeps a Buy rating on the shares.
Outset Medical price target lowered to $6 from $8 at Stifel
Stifel lowered the firm’s price target on Outset Medical (OM) to $6 from $8 and keeps a Buy rating on the shares.
Outset Medical reports Q1 EPS ($1.03), consensus (79c)
Reports Q1 revenue $27.86M, consensus $28.9M. “We delivered a solid first quarter and continued to make meaningful progress on our path to profitability, driven by disciplined execution and another qu...
Outset Medical backs FY26 revenue view $125M-$130M, consensus $126.77M
The company said, “Outset reiterated its 2026 revenue guidance of $125 million to $130 million, a 5% to 9% increase over $119.5 million in 2025, and non-GAAP gross margin guidance
Outset Medical Earnings Call Transcript: Q1 2026
Q1 2026 revenue declined 6% year-over-year to $27.9M due to capital order timing, but gross margin expanded and recurring revenue remained stable. Guidance for 2026 is reaffirmed, with most growth expected in the second half, driven by next-gen Tablo and a robust pipeline.
Outset Medical Reports First-Quarter Results
SAN JOSE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis wi...
Outset Medical to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
SAN JOSE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes i...
Did Outset Medical, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you ...
Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN JOSE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first of-its-kind technology to improve clinical outcomes in dialysis ...
Outset Medical Names Derick Elliott as Executive Vice President of Commercial
SAN JOSE, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis ...
Outset Medical price target lowered to $12 from $15 at TD Cowen
TD Cowen lowered the firm’s price target on Outset Medical (OM) to $12 from $15 and keeps a Buy rating on the shares. The firm said the company’s results met
Outset Medical price target lowered to $15 from $17 at BTIG
BTIG analyst Marie Thibault lowered the firm’s price target on Outset Medical (OM) to $15 from $17 and keeps a Buy rating on the shares. With stability in the company’s
Outset Medical Earnings Call Transcript: Q4 2025
Revenue grew 5% in 2025 to $119.5M, with gross margin expansion and reduced cash burn. FDA clearance of the next-gen Tablo platform positions the company for further growth, with 2026 revenue guidance of $125M–$130M and continued margin improvement.
Outset Medical reports Q4 EPS ($1.09), consensus (68c)
Reports Q4 revenue $28.87M, consensus $28.9M. “We enter 2026 standing on a strong foundation for growth, well capitalized, and with a highly differentiated platform to help healthcare providers transf...
Outset Medical sees FY26 revenue $125M-$130M, consensus $127.64M
The company said, “Outset provided 2026 revenue guidance of $125 million to $130 million, a 5% to 9% increase over $119.5 million in 2025, and non-GAAP gross margin guidance in
Outset Medical Reports Fourth Quarter and Full Year 2025 Financial Results
SAN JOSE, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less...
Outset Medical says next-generation Tablo platform receives FDA clearance
Outset Medical (OM) announced 510(k) clearance by the U.S. Food and Drug Administration of its next-generation Tablo platform, designed to deliver enterprise-level security, reliability and connectivi...
Next-Generation Tablo Hemodialysis System Receives FDA Clearance, Second Quarter Launch Planned
SAN JOSE, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis w...
Outset Medical to Report Fourth Quarter 2025 Financial Results on Wednesday, February 11, 2026
SAN JOSE, Calif., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...
Outset Medical Transcript: 44th Annual J.P. Morgan Healthcare Conference
Operating at scale in acute and home dialysis markets, the company leverages innovative technology and a recurring revenue model to drive growth and improve patient outcomes. Strong financials, high retention rates, and a focus on gross margin expansion position it for continued market share gains and profitability.
Outset Medical reports Q4 revenue $28.9M, consensus $26.15M
“We enter 2026 with a strong backlog, a growing pipeline of new opportunities and a great deal of confidence that the value we deliver for providers and dialysis patients can
Outset Medical appoints Prange to its board of directors
Outset Medical (OM) announced the appointment of Karen Prange to its board of directors and its Compensation Committee, replacing Andrea Saia who served on the board since March of 2021.
Outset Medical Reports Unaudited Fourth Quarter and 2025 Results
SAN JOSE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, tod...
Outset Medical price target lowered to $8 from $14 at Stifel
Stifel analyst Rick Wise lowered the firm’s price target on Outset Medical (OM) to $8 from $14 and keeps a Buy rating on the shares. The firm, which argues that
Outset Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN JOSE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexi...